Financials
Financial year 2025
D2S Pharma from Oudenaarde, company number BE0563446868, closed financial year 2025 with a result of € 38,474 after tax. For that financial year D2S Pharma recorded a gross margin of € 129,195 and equity of € 424,697. Compared with financial year 2024, the result moved from € 17,705 to € 38,474. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on February 20, 2026.
€ 424,697
▲ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 38,474
▲ 117% vs 2024
Profit after tax over the fiscal year.
€ 188,504
▲ 33% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 324,697.
People and assets in 2025
0.5
▼ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 26,909
▼ 16% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,337
▼ 46% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 69,506
▼ 17% vs 2024
€ 9,503 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 55,936
▲ 99% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 9,154
▼ 11% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 85,449 | € 73,834 | € 111,075 | € 129,195 | ▲ 16% |
| Profit after taxes | € 12,312 | € 2,575 | € 17,705 | € 38,474 | ▲ 117% |
| Equity | € 365,944 | € 368,518 | € 386,223 | € 424,697 | ▲ 10% |
| Total debts | € 233,960 | € 188,515 | € 150,186 | € 157,621 | ▲ 5% |
| Cash | € 135,136 | € 144,570 | € 142,011 | € 188,504 | ▲ 33% |
| Retained profit | € 265,944 | € 268,518 | € 286,223 | € 324,697 | ▲ 13% |
| Bank debt | € 146,118 | € 112,483 | € 83,659 | € 69,506 | ▼ 17% |
| Balance sheet total | € 599,904 | € 557,033 | € 536,409 | € 582,318 | ▲ 9% |
| Employees (FTE) | 0.6 | 0.5 | 0.6 | 0.5 | ▼ 0.1 |
Key figures of D2S Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to D2S Pharma?
What happened at D2S Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 38,474 (▲ 117% vs 2024). filed late Source: NBB ↗
- New establishment in Oudenaarde. KBO
- Start of the company according to the CBE. KBO
In short
From € 12,312 profit in 2022 to € 38,474 profit in 2025.
Paid € 27,191 in corporate taxes since 2022.
Best year ever: 2025, with € 38,474 profit.
Management
Behind D2S Pharma is Lumadec BV. Lumadec BV is also behind CARUUR.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Berchemweg 139
9700 Oudenaarde
Paalstraat 16
9700 Oudenaarde
Active since 30 September 2014
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0563.446.868
- VAT number
- BE 0563.446.868
- Registered office
- Berchemweg 139, 9700 Oudenaarde
- Names & denominations
- D2S Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 September 2014
- Peppol
- Active · Active since 12 Dec 2025
- Contact
- [email protected]
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van parfums en toiletartikelen
Groothandel in farmaceutische en medische artikelen
Overige zakelijke dienstverlening, neg